Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager (The Manila Times) - May 26, 2026 - "CLN-978 (CD19xCD3 T cell engager): treatment-refractory moderate to severe SLE and difficult-to-treat RA: Single target dose escalation data in SLE and RA, as reported at EULAR 2026 Congress on June 6, 2026; Initial data from the first multi-dose cohort of the RA study; Next steps in global clinical development...Velinotamig (BCMAxCD3 T cell engager): treatment-refractory autoimmune diseases driven by long-lived plasma cells: Initial data from the first multi-dose cohort of the Genrix Bio study in China; Next steps in global clinical development."
P1 data • Immunology • Rheumatoid Arthritis • Systemic Lupus Erythematosus
|